The Lung Cancer Study Group (LCSG) 
The Lung Cancer Study Group (4) subcarinal lymph node plus one other site identified in patient groups 1, 2, and 3 (43 patients).6 Analysis of recurrence rates and death r-ates for these groups of patients revealed an increased probability of recurrence or death for patients in group 4 compared with patients in group 3 (Fig 1) . Therefore, it is essential that all anatomically identifiable lymph node locations be histologically examined in patients with lung cancer to define the extent of disease and for prognostic assessment as a guide to management. Pilot studies have demonstrated the feasibility of converting nonresectable lung cancers to resectable in patients with locally advanced cancer by neoadjuvant treatment.10'11 Histopathologic staging prior to the initiation of neoadjuvant therapy and again at the time of surgical intervention is critical for objective assessment of the extent of malignancy and the therapeutic response. Therefore, mediastinoscopy and histologic examination of mediastinal lymph nodes must be required for pretreatment clinical staging of patients selected for neoadjuvant therapy. In a retrospective analysis of 58 -patients with stage IIIA lung cancer, a total of 170 mediastinal lymph node sites were biopsied at mediastinoscopy.12 The primary lung cancer was in the right lung in 66% of patients. Seventy-eight biopsies were positive histologically for malignancy. Almost half of the nonmalignant lymph nodes (44 of 92) were recovered from contralateral mediastinal or hilar locations. As a result of this study, the LCSG was confident that sufficient mediastinal lymph node staging is possible via mediastinoscopy to define patients suitable for accrual to neoadjuvant treatment for locally advanced lung cancer. 
CONCLUSIONS

